Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the COVID-19 vaccine Spikevax®, targeting the ...

Leveraging the power of Microsoft Cloud for health authority queries to create streamlined, efficient processes.

MetrioPharm’s lead compound, MP1032, has received ODD from the European Medicines Agency (EMA) for treating DMD in children.

Regulators block Duchenne muscular dystrophy treatment after fatal side-effects outweigh questionable efficacy ...

Reduce development timelines and costs, while improving access to life-saving treatments VANCOUVER, BC / ACCESS Newswire / July 30, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfur ...

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced a comprehensive market and strategy update after successfully securing full funding for its BupiZenge Phase 3 clinical trial aimed at ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Following the FDA approval of linvoseltamab (Lynozyfic; Regeneron) for heavily pretreated multiple myeloma, Sundar Jagannath, MBBS, highlights its potential for earlier use, increased accessibility, ...

Bausch Health to acquire DURECT Corporation, strengthening commitment to developing innovative solutions for patients with liver disease: Laval, Quebec Wednesday, July 30, 2025, 1 ...

Alfasigma announces positive results from OLINGUITO phase 3 trial of filgotinib to treat adult patients with active axial spondyloarthritis: Bologna Wednesday, July 30, 2025, 18:0 ...

Though India has built a robust domestic biosimilar market, its international presence and the ability to lower prices as ...